PL1963292T3 - Związki organiczne - Google Patents
Związki organiczneInfo
- Publication number
- PL1963292T3 PL1963292T3 PL06839094T PL06839094T PL1963292T3 PL 1963292 T3 PL1963292 T3 PL 1963292T3 PL 06839094 T PL06839094 T PL 06839094T PL 06839094 T PL06839094 T PL 06839094T PL 1963292 T3 PL1963292 T3 PL 1963292T3
- Authority
- PL
- Poland
- Prior art keywords
- organic compounds
- compounds
- organic
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74857305P | 2005-12-08 | 2005-12-08 | |
| EP06839094A EP1963292B1 (en) | 2005-12-08 | 2006-12-06 | Organic compounds |
| PCT/US2006/046545 WO2007067615A2 (en) | 2005-12-08 | 2006-12-06 | Thiadiazole derivatives as antidiabetic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1963292T3 true PL1963292T3 (pl) | 2012-07-31 |
Family
ID=37950917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06839094T PL1963292T3 (pl) | 2005-12-08 | 2006-12-06 | Związki organiczne |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7700633B2 (pl) |
| EP (1) | EP1963292B1 (pl) |
| JP (1) | JP2009519248A (pl) |
| KR (1) | KR20080074969A (pl) |
| CN (1) | CN101326173A (pl) |
| AR (1) | AR056838A1 (pl) |
| AT (1) | ATE546440T1 (pl) |
| AU (1) | AU2006321905B2 (pl) |
| BR (1) | BRPI0619600A2 (pl) |
| CA (1) | CA2629857A1 (pl) |
| CR (1) | CR10049A (pl) |
| EC (1) | ECSP088506A (pl) |
| ES (1) | ES2381280T3 (pl) |
| IL (1) | IL191549A0 (pl) |
| MA (1) | MA30202B1 (pl) |
| NO (1) | NO20083031L (pl) |
| NZ (1) | NZ568243A (pl) |
| PE (2) | PE20071031A1 (pl) |
| PL (1) | PL1963292T3 (pl) |
| PT (1) | PT1963292E (pl) |
| RU (1) | RU2008127254A (pl) |
| TN (1) | TNSN08249A1 (pl) |
| TW (1) | TW200732315A (pl) |
| UA (1) | UA94724C2 (pl) |
| WO (1) | WO2007067615A2 (pl) |
| ZA (1) | ZA200804074B (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009518421A (ja) * | 2005-12-08 | 2009-05-07 | ノバルティス アクチエンゲゼルシャフト | １，１，３−トリオキソ−１，２，５−チアジアゾリジンおよびＰＴＰａｓｅ阻害剤としてのそれらの使用 |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| KR20080074970A (ko) * | 2005-12-08 | 2008-08-13 | 노파르티스 아게 | 단백질 티로신 포스파타제 (ｐｔｐａｓｅ)에 의해 매개되는질병의 치료에 유용한 1,2,5-티아졸리딘 유도체 |
| WO2008067527A1 (en) * | 2006-12-01 | 2008-06-05 | Novartis Ag | Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders |
| AR066820A1 (es) * | 2007-06-04 | 2009-09-16 | Novartis Ag | Compuestos de tiadiazolidin-3 ona |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| AU2011313191A1 (en) | 2010-10-08 | 2013-05-02 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| AU2012248627A1 (en) | 2011-04-28 | 2013-11-14 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| AU2017383102B2 (en) * | 2016-12-23 | 2023-05-11 | The University Of Queensland | Inhibitors of SOX18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases |
| PE20210372A1 (es) * | 2018-06-21 | 2021-02-26 | Abbvie Inc | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso |
| US12492180B2 (en) | 2018-12-21 | 2025-12-09 | Curia Spain, S.A.U. | Process and intermediates for the preparation of Voxelotor |
| AU2020234712B2 (en) * | 2019-03-14 | 2025-12-04 | Abbvie Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| WO2021119554A1 (en) | 2019-12-12 | 2021-06-17 | Kumquat Biosciences Inc. | Compositions and methods for potentiating immune activity |
| WO2021127586A1 (en) * | 2019-12-20 | 2021-06-24 | Calico Life Sciences Llc | Protein tyrosine phosphatase degraders and methods of use thereof |
| CN117279913A (zh) * | 2021-03-11 | 2023-12-22 | 金橘生物科技公司 | 杂环化合物及其用途 |
| AU2022387106A1 (en) * | 2021-11-11 | 2024-05-23 | Abbvie Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| EP4472958A1 (en) * | 2022-02-02 | 2024-12-11 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
| TW202337459A (zh) * | 2022-02-02 | 2023-10-01 | 美商耐瑞歐醫療公司 | 蛋白酪胺酸磷酸酶抑制劑及其用途 |
| JP2025505994A (ja) * | 2022-02-02 | 2025-03-05 | ネリオ セラピューティクス，インク． | プロテインチロシンホスファターゼ阻害剤およびその使用 |
| EP4587436A1 (en) * | 2022-09-13 | 2025-07-23 | Kumquat Biosciences Inc. | Benzo-fused n-heterocycles and uses thereof |
| WO2024067802A1 (zh) * | 2022-09-30 | 2024-04-04 | 深圳众格生物科技有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途 |
| WO2024141015A1 (en) * | 2022-12-30 | 2024-07-04 | Insilico Medicine Ip Limited | Protein tyrosine phosphatase inhibitors and uses thereof |
| CN118852335A (zh) * | 2023-04-28 | 2024-10-29 | 中科中山药物创新研究院 | 噻二唑烷酮衍生物及其制备方法和应用 |
| CN116496248B (zh) * | 2023-05-06 | 2025-09-02 | 江苏艾科姆检测有限公司 | 一种溴氰虫酰胺杂质的合成方法 |
| TW202500126A (zh) | 2023-05-24 | 2025-01-01 | 美商金橘生物科技公司 | 雜環化合物及其用途 |
| CN121443598A (zh) * | 2023-07-11 | 2026-01-30 | 深圳众格生物科技有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途 |
| CN120004876B (zh) * | 2023-11-16 | 2026-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| WO2025242216A1 (zh) * | 2024-05-24 | 2025-11-27 | 杭州百新生物医药科技有限公司 | 吲哚啉类化合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003082841A1 (en) | 2002-04-03 | 2003-10-09 | Novartis Ag | 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors |
| GB0225986D0 (en) * | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
| EP1594497B1 (en) * | 2002-12-30 | 2009-05-27 | Vertex Pharmaceuticals Incorporated | Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
| WO2005035551A2 (en) * | 2003-10-08 | 2005-04-21 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
| JP2009518421A (ja) | 2005-12-08 | 2009-05-07 | ノバルティス アクチエンゲゼルシャフト | １，１，３−トリオキソ−１，２，５−チアジアゾリジンおよびＰＴＰａｓｅ阻害剤としてのそれらの使用 |
| KR20080074970A (ko) | 2005-12-08 | 2008-08-13 | 노파르티스 아게 | 단백질 티로신 포스파타제 (ｐｔｐａｓｅ)에 의해 매개되는질병의 치료에 유용한 1,2,5-티아졸리딘 유도체 |
| CN101421256A (zh) | 2006-03-31 | 2009-04-29 | 诺瓦提斯公司 | 蛋白酪氨酸磷酸酶的噻二唑烷酮抑制剂 |
-
2006
- 2006-06-12 UA UAA200807751A patent/UA94724C2/ru unknown
- 2006-12-06 JP JP2008544467A patent/JP2009519248A/ja active Pending
- 2006-12-06 PL PL06839094T patent/PL1963292T3/pl unknown
- 2006-12-06 EP EP06839094A patent/EP1963292B1/en active Active
- 2006-12-06 AT AT06839094T patent/ATE546440T1/de active
- 2006-12-06 CA CA002629857A patent/CA2629857A1/en not_active Abandoned
- 2006-12-06 BR BRPI0619600-4A patent/BRPI0619600A2/pt not_active IP Right Cessation
- 2006-12-06 ES ES06839094T patent/ES2381280T3/es active Active
- 2006-12-06 RU RU2008127254/04A patent/RU2008127254A/ru not_active Application Discontinuation
- 2006-12-06 AR ARP060105392A patent/AR056838A1/es not_active Application Discontinuation
- 2006-12-06 PE PE2006001571A patent/PE20071031A1/es not_active Application Discontinuation
- 2006-12-06 PT PT06839094T patent/PT1963292E/pt unknown
- 2006-12-06 KR KR1020087013716A patent/KR20080074969A/ko not_active Ceased
- 2006-12-06 US US12/096,439 patent/US7700633B2/en not_active Expired - Fee Related
- 2006-12-06 WO PCT/US2006/046545 patent/WO2007067615A2/en not_active Ceased
- 2006-12-06 PE PE2010000531A patent/PE20100733A1/es not_active Application Discontinuation
- 2006-12-06 AU AU2006321905A patent/AU2006321905B2/en not_active Ceased
- 2006-12-06 CN CNA2006800461637A patent/CN101326173A/zh active Pending
- 2006-12-06 NZ NZ568243A patent/NZ568243A/en not_active IP Right Cessation
- 2006-12-07 TW TW095145713A patent/TW200732315A/zh unknown
-
2008
- 2008-05-13 ZA ZA200804074A patent/ZA200804074B/xx unknown
- 2008-05-19 IL IL191549A patent/IL191549A0/en unknown
- 2008-06-02 MA MA30987A patent/MA30202B1/fr unknown
- 2008-06-05 CR CR10049A patent/CR10049A/es not_active Application Discontinuation
- 2008-06-06 EC EC2008008506A patent/ECSP088506A/es unknown
- 2008-06-06 TN TNP2008000249A patent/TNSN08249A1/en unknown
- 2008-07-04 NO NO20083031A patent/NO20083031L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007067615A2 (en) | 2007-06-14 |
| MA30202B1 (fr) | 2009-02-02 |
| CR10049A (es) | 2008-08-25 |
| US20080262050A1 (en) | 2008-10-23 |
| ES2381280T3 (es) | 2012-05-24 |
| TW200732315A (en) | 2007-09-01 |
| UA94724C2 (en) | 2011-06-10 |
| ECSP088506A (es) | 2008-07-30 |
| CA2629857A1 (en) | 2007-06-14 |
| EP1963292B1 (en) | 2012-02-22 |
| US7700633B2 (en) | 2010-04-20 |
| PE20100733A1 (es) | 2010-10-29 |
| WO2007067615A3 (en) | 2007-11-15 |
| AU2006321905A1 (en) | 2007-06-14 |
| PT1963292E (pt) | 2012-05-10 |
| IL191549A0 (en) | 2008-12-29 |
| PE20071031A1 (es) | 2007-11-15 |
| JP2009519248A (ja) | 2009-05-14 |
| NZ568243A (en) | 2011-07-29 |
| AU2006321905B2 (en) | 2011-08-11 |
| RU2008127254A (ru) | 2010-01-20 |
| AR056838A1 (es) | 2007-10-24 |
| KR20080074969A (ko) | 2008-08-13 |
| CN101326173A (zh) | 2008-12-17 |
| EP1963292A2 (en) | 2008-09-03 |
| BRPI0619600A2 (pt) | 2011-10-11 |
| NO20083031L (no) | 2008-08-28 |
| TNSN08249A1 (en) | 2009-10-30 |
| ATE546440T1 (de) | 2012-03-15 |
| ZA200804074B (en) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0510390D0 (en) | Organic compounds | |
| GB0507575D0 (en) | Organic compounds | |
| GB0500435D0 (en) | Organic compounds | |
| PL1963292T3 (pl) | Związki organiczne | |
| GB0500785D0 (en) | Organic compounds | |
| GB0508319D0 (en) | Organic compounds | |
| GB0505969D0 (en) | Organic compounds | |
| GB0502358D0 (en) | Organic compounds | |
| GB0505219D0 (en) | Organic compounds | |
| GB0503646D0 (en) | Organic compounds | |
| GB0507298D0 (en) | Organic compounds | |
| GB0504850D0 (en) | Organic compounds | |
| GB0504194D0 (en) | Organic compounds | |
| GB0511060D0 (en) | Organic compounds | |
| GB0510810D0 (en) | Organic compounds | |
| GB0504544D0 (en) | Organic compounds | |
| GB0508992D0 (en) | Organic compounds | |
| GB0514296D0 (en) | Organic compounds | |
| GB0501237D0 (en) | Organic compounds | |
| GB0500784D0 (en) | Organic compounds | |
| GB0504203D0 (en) | Organic compounds | |
| GB0500020D0 (en) | Organic compounds | |
| GB0507695D0 (en) | Organic compounds | |
| GB0505541D0 (en) | Organic compounds | |
| GB0511063D0 (en) | Organic compounds |